Switzerland is home to a thriving pharmaceutical industry. (Keystone) - Click to enlarge The United States Food and Drug Administration (FDA) published Thursday a list of pharmaceutical companies that include Basel-based Novartis and Roche, all of which are suspected of hindering the development of generic versions of their own medicines. Over 150 complaints were filed. The FDA slammed the development of techniques designed to complicate or even prevent developers of generic drugs from accessing sufficient quantities of original preparations to be able to do comparative studies essential to any application for approval. The authority said it has received more than 150 complaints over the alleged misuse of FDA
Topics:
Swissinfo considers the following as important: 3) Swiss Markets and News, Business, Featured, newsletter
This could be interesting, too:
Eamonn Sheridan writes CHF traders note – Two Swiss National Bank speakers due Thursday, November 21
Charles Hugh Smith writes How Do We Fix the Collapse of Quality?
Marc Chandler writes Sterling and Gilts Pressed Lower by Firmer CPI
Michael Lebowitz writes Trump Tariffs Are Inflationary Claim The Experts
The United States Food and Drug Administration (FDA) published Thursday a list of pharmaceutical companies that include Basel-based Novartis and Roche, all of which are suspected of hindering the development of generic versions of their own medicines. Over 150 complaints were filed.
The FDA slammed the development of techniques designed to complicate or even prevent developers of generic drugs from accessing sufficient quantities of original preparations to be able to do comparative studies essential to any application for approval.
The authority said it has received more than 150 complaints over the alleged misuse of FDA programmes or agreements between pharmaceutical companies and distributors.
The FDA noted that it had not investigated these allegations.
Tags: Business,Featured,newsletter